TY - JOUR
T1 - Research involving fetal drug therapy
T2 - Ethical, legal, and practical considerations
AU - Prentice, E. D.
AU - Rayburn, W. F.
PY - 1991
Y1 - 1991
N2 - Fetal drug therapies have emerged as a promising avenue for the prevention or correction of disease during fetal or immediate postnatal life. Despite slow progress, several medications have been developed for in utero therapy of disorders which relate to fetal and neonatal pulmonary, cardiac, neurologic, and growth disorders. However, ethical and regulatory constraints require protection of the mother and fetus while causing no more than necessary additional risk. Appreciating these constraints will lead to the identification of pragmatic questions which should be answered before evaluating the efficacy and safety of a particular treatment or research proposal.
AB - Fetal drug therapies have emerged as a promising avenue for the prevention or correction of disease during fetal or immediate postnatal life. Despite slow progress, several medications have been developed for in utero therapy of disorders which relate to fetal and neonatal pulmonary, cardiac, neurologic, and growth disorders. However, ethical and regulatory constraints require protection of the mother and fetus while causing no more than necessary additional risk. Appreciating these constraints will lead to the identification of pragmatic questions which should be answered before evaluating the efficacy and safety of a particular treatment or research proposal.
UR - http://www.scopus.com/inward/record.url?scp=0025727169&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025727169&partnerID=8YFLogxK
U2 - 10.1097/00003081-199106000-00018
DO - 10.1097/00003081-199106000-00018
M3 - Article
C2 - 1868643
AN - SCOPUS:0025727169
SN - 0009-9201
VL - 34
SP - 360
EP - 368
JO - Clinical obstetrics and gynecology
JF - Clinical obstetrics and gynecology
IS - 2
ER -